Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.